Sermorelin

What is sermorelin?

Sermorelin is a synthetic version of the first 29 amino acids of growth hormone-releasing hormone (GHRH), the hypothalamic hormone that tells the pituitary gland to release growth hormone. This 29-amino-acid fragment, sometimes called GRF 1-29, is the shortest piece of GHRH that keeps full biological activity.

Serono marketed sermorelin in the US as Geref. It was used as a diagnostic test of the pituitary's ability to release growth hormone and to treat children with growth hormone deficiency. Serono stopped making Geref in 2008, and the FDA later determined that the product was not withdrawn for safety or effectiveness reasons. Since then, sermorelin has been available in the US mainly through compounding pharmacies.

Today it is best known as an 'anti-aging' or wellness peptide, prescribed by men's health, longevity and telehealth clinics for energy, sleep, body composition and recovery. Those uses were never part of its approved labeling.

How sermorelin works

Growth hormone is released in pulses, mostly during deep sleep, under the control of two brain signals: GHRH, which turns release on, and somatostatin, which turns it off. Sermorelin mimics the 'on' signal. It prompts the pituitary to make and release its own growth hormone, which then raises IGF-1, the hormone that carries out many of growth hormone's effects. Because the body's own brakes still work, levels are less likely to climb as high as with injected growth hormone.

Technically, sermorelin is GHRH(1-29)-NH2. It binds the GHRH receptor, a G-protein-coupled receptor on somatotroph cells of the anterior pituitary, increasing cAMP and stimulating both synthesis and pulsatile secretion of growth hormone. Its half-life is only about 10 to 20 minutes, so it produces a short pulse rather than sustained exposure. Release remains subject to negative feedback from somatostatin and IGF-1, and the response depends on a functioning pituitary. Reviews classify sermorelin with other growth hormone secretagogues that act through the IGF-1 axis¹.

What the research shows on sermorelin

The strongest human data are old and relate to its original uses. As a diagnostic agent, intravenous Geref was used to test pituitary growth hormone reserve, including in research on how cranial irradiation affects growth hormone secretion⁷ and how high-altitude living changes pituitary responses⁵. In both, sermorelin served as a tool to provoke growth hormone release, not as a treatment.

As a treatment for children with growth hormone deficiency, sermorelin worked for some but not all. In one follow-up study, 27 children who left a Geref trial, mostly because their growth rate was inadequate, were switched to recombinant growth hormone and responded well⁸. That pattern is a key reason recombinant growth hormone, not sermorelin, became standard care for childhood deficiency.

For adults, the case rests largely on small studies and expert opinion. A 2006 commentary argued that sermorelin might be a better approach to adult-onset growth hormone insufficiency than direct growth hormone replacement because it preserves feedback control⁴. Small older trials in older adults reported modest rises in growth hormone and IGF-1, with inconsistent effects on body composition, strength or wellbeing. There are no large, modern randomized trials showing that sermorelin improves sleep, body fat, muscle, recovery or longevity in healthy adults.

Recent reviews of peptide use in sport and musculoskeletal medicine list sermorelin among peptides promoted for recovery and performance, and conclude that rigorous human evidence for those uses is lacking²⁶.

Studied for: Growth hormone deficiency diagnosis and paediatric treatment, Age-related GH decline, Sleep quality, Body composition.

Sermorelin reference data

Sermorelin dosage in published research

Open this in the dosage calculator ↗

How sermorelin is used in practice

In current US practice, sermorelin is mostly prescribed by wellness, anti-aging and telehealth clinics and dispensed by compounding pharmacies as a powder that is mixed with sterile water for injection. It is usually injected under the skin at bedtime to coincide with the natural nighttime growth hormone pulse, often for courses of several months. Some clinics check IGF-1 before and during treatment, others do not. Compounded sermorelin is not FDA-approved, so its quality depends on the pharmacy. Clinics often combine it with growth hormone-releasing peptides such as ipamorelin, on the theory that the two signals work together. Those combinations have even less clinical data than sermorelin alone.

Sermorelin is also sold by research-peptide websites, where identity, purity and sterility are unverified. Reviews of the gray market note that products are often mislabeled or contaminated⁶. Athletes should know that GHRH and its analogs, including sermorelin, are prohibited by the World Anti-Doping Agency, and laboratories have developed methods to detect sermorelin and its metabolites in urine³.

Sermorelin risks and side effects

Short-term side effects are usually mild: redness, swelling or pain at the injection site, flushing, headache and occasional dizziness. Allergic reactions are possible.

Longer-term risks mirror the concerns with raising growth hormone and IGF-1: fluid retention, joint pain, reduced insulin sensitivity and, in theory, promotion of existing tumors, which is why active cancer is a contraindication. Glucocorticoids, somatostatin analogs and thyroid status can change the response. Sermorelin should not be used in pregnancy. Because it relies on a working pituitary, it does little for people whose pituitary is damaged, and using it without proper testing can delay the diagnosis of a real hormone problem.

The biggest unknown is long-term use in healthy adults, which has never been studied properly. Reviews of peptide use in sport warn of possible insulin resistance and other metabolic harms with unsupervised use, and of an unregulated supply chain⁶.

Reported side effects

Alternatives to sermorelin

For confirmed growth hormone deficiency in children or adults, FDA-approved recombinant growth hormone (somatropin) and long-acting versions such as somapacitan, somatrogon and lonapegsomatropin are the standard of care. Macimorelin (Macrilen) is an approved oral test for adult growth hormone deficiency. Tesamorelin (Egrifta), a GHRH analog, is FDA-approved for reducing excess abdominal fat in people with HIV-associated lipodystrophy.

For the goals clinics usually target, such as better sleep, more muscle and less fat, the best-evidenced options are resistance training, adequate protein, weight loss where appropriate, consistent sleep habits and treatment of sleep apnea. Low testosterone, thyroid disease and depression should be ruled out when fatigue is the main complaint.

Questions for a clinician

• What evidence applies to my situation, and at what level?
• What established alternatives should I consider first?
• What monitoring would be necessary, and how often?